Evidence map›Paper›PMID 38472514›Full record

ArticleCellular and molecular life sciences : CMLS2024

Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech.

Aditi Pradhan, Hayley Mounford, Jessica Peixinho, Edward Rea, Emmanouela Epeslidou, Julia S Scott, Joanna Cull, Susan Maxwell, Richard Webster, David Beeson and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Evaluation of [Receptors (Basel, Switzerland) · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Aditi PradhanDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.
Hayley MounfordDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.ORCID http://orcid.org/0000-0002-7663-6326
Jessica PeixinhoDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.
Edward ReaDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.
Emmanouela EpeslidouCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Julia S ScottCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Joanna CullDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.
Susan MaxwellNeurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, England.ORCID http://orcid.org/0009-0009-6514-149X
Richard WebsterNeurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, England.ORCID http://orcid.org/0000-0001-7893-1348
David BeesonNeurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, England.ORCID http://orcid.org/0000-0001-9395-7132
Yin Yao DongNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DS, England.ORCID http://orcid.org/0000-0001-8600-6988
Stefan PrekovicCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7051-9321
Isabel BermudezDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England.ORCID http://orcid.org/0000-0001-7692-1509
Dianne F NewburyDepartment of Biological and Molecular Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, OX3 0BP, England. diannenewbury@brookes.ac.uk.ORCID http://orcid.org/0000-0002-9557-268X
Oxford Brookes University · GBJohn Radcliffe Hospital · GBUniversity Medical Center Utrecht · NLUniversity of Oxford · GB

Funding

Medical Research Council MR/M006824/1MRF MR/M006824/1MRF MR/S007180/M
6 · The paper itself

Abstract

Recent work putatively linked a rare genetic variant of the chaperone Resistant to Inhibitors of acetylcholinesterase (RIC3) (NM_024557.4:c.262G > A, NP_078833.3:p.G88R) to a unique ability to speak backwards, a language skill that is associated with exceptional working memory capacity. RIC3 is important for the folding, maturation, and functional expression of α7 nicotinic acetylcholine receptors (nAChR). We compared and contrasted the effects of RIC3G88R on assembly, cell surface expression, and function of human α7 receptors using fluorescent protein tagged α7 nAChR and Förster resonance energy transfer (FRET) microscopy imaging in combination with functional assays and

Indexed as

Receptors, NicotinicAcetylcholinesterasealpha7 Nicotinic Acetylcholine ReceptorCell MembraneHumansIntracellular Signaling Peptides and ProteinsSpeechAcetylcholinesterasealpha7 Nicotinic Acetylcholine ReceptorChrna7 protein, humanIntracellular Signaling Peptides and ProteinsReceptors, NicotinicRIC3 protein, humanBackward speechNicotinic acetylcholine receptorsRIC3

Identifiers

PMID38472514
PMCPMC10933150
OpenAlexW4394740611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.